NEUVIOR Data Analysis
Evidence worth
looking into.
Public data.
Original questions.
Analysis you can inspect.
Medicine produces extraordinary amounts of information. Its value depends on whether the right people can understand what it means, where it comes from and what question to ask next.
We are building a public analysis layer around that work: reproducible views of medicines activity, a transparent source catalogue and a clear path from an observation to a question worth testing.
Public medicines analysis | England 2025/26
The landscape
behind the leaders.
1,944 groups. Two different measures. Explore the distance between dispensing activity and ingredient cost.
Each point represents one medicinal BNF chemical-substance group. Move across to more prescription items; move up to more total NIC.
1,944 matching groups.
Both axes use log10 scales. Equal spacing means a tenfold difference.
Select a point in the landscape, or use this native selector. Search narrows its options. Names and BNF codes follow the source. On a narrow display, slide the landscape horizontally to inspect its full scale.
Read the scales, boundary and source
Both axes are logarithmic to reveal groups across a wide range. Equal spacing means multiplying by ten; it does not mean adding the same number. Axis bounds are fixed to the complete medicinal snapshot, so chapter and search selections do not change a point’s position. Every point has the same base size; point area does not encode volume or cost.
Only finite, strictly positive item and NIC values can have log coordinates. 0 groups are excluded from this snapshot’s plot for non-positive or non-finite values. If such a source value is present, it remains available in the matching selector and exact-value panel; it is not moved to an invented positive value.
Activity and NIC emphasise the respective national top ten, with ties resolved by original BNF code. They do not fit a trend line, measure correlation, identify patient diagnoses or establish value, waste or market opportunity. Overlapping points can conceal one another; the native selector remains available for every matching source row.
NHSBSA’s Prescription Cost Analysis covers England’s community dispensing. This view retains medicinal chapters 01–15 and excludes pseudo chapters. Source-derived totals: 1,239,249,027 items and £9,983,762,289.24 NIC. Search and chapter selection do not replace these national denominators or ranks.
NHSBSA (2026) | Prescription Cost Analysis – England 2025/26. Workbook published 2026-06-04; source snapshot verified 13 October 2026. Chemical_Substances worksheet. Contains public sector information licensed under the Open Government Licence v3.0.
Keep the complete 1,944-row analysisInspect the original workbook
NEUVIOR Data Analysis | Public analysis
Different leaders.
Different questions.
The most dispensed groups and the highest ingredient-cost groups tell different stories.
We examined all 1,944 medicinal chemical-substance groups in England’s published 2025/26 community dispensing data. The two top-ten lists have no shared group.
Medicinal BNF chapters 01–15 | 1,239,249,027 items | £9,983,762,289.24 NIC
of medicinal items in the 10 activity leaders
of medicinal NIC in the 10 cost leaders
groups appear in both lists
Each percentage uses its own top-10 list and the complete medicinal denominator. These are different cohorts, not the same groups measured twice.
The activity leaders
The 10 highest groups by items.
The ingredient-cost leaders
The 10 highest groups by NIC.
Methods, source and limitations
NEUVIOR analysis of the Chemical_Substances worksheet in NHSBSA’s Prescription Cost Analysis, England 2025/26. We retained chapters 01–15, ranked the exact item counts and integer-pence NIC values separately, and resolved ties by the original BNF code. All 1,944 codes are unique. Every medicinal chapter and the combined medicinal total reconcile to the source with no item or penny difference.
These are BNF classification groups, including combinations and vaccines. Source names are preserved. Groups do not establish a diagnosis, a single medicine price or the full expenditure of a therapy across all care settings. NIC divided by items is a mix-dependent aggregate, not a comparable unit price or achievable saving.
The workbook was published 4 June 2026 and the local source snapshot was verified 13 October 2026. The analysis period is 1 April 2025 to 31 March 2026. This is a versioned snapshot, not a live dispensing feed.
Contains public sector information licensed under the Open Government Licence v3.0. NHSBSA (2026) Prescription Cost Analysis – England 2025/26.
Download the 1,944 source-derived rowsInspect the original workbook
Source watch | MHRA
Information changes.
Keep the source
in view.
The original communication matters.
Our retrieved MHRA feed snapshot indexes official medicines and device communications. These links illustrate the source; they do not replace its full instructions, amendments or current status.
Snapshot retrieved 13 October 2026 | Feed source updated 13 October 2026 | 50 entries captured
Source updated 13 October 2026
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014
Read the full official MHRA communication and its current amendments.
Source updated 12 October 2026
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Read the full official MHRA communication and its current amendments.
Source updated 9 October 2026
Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013
Read the full official MHRA communication and its current amendments.
A bounded 50-entry feed snapshot. Updated timestamps are not necessarily first-publication dates. Not a complete historical recall inventory. This snapshot does not provide a live recall-monitoring or product-matching service.
NEUVIOR Data Analysis | Public research analysis
Registered.
Completed.
Results posted?
Three different facts about a study.
We examined the public metadata returned by a ClinicalTrials.gov condition search for glioblastoma. The complete search returned 2,273 records; 1,773 contain “glioblastoma” in at least one submitted condition label.
Explore that explicit-label subset or the broader search, then separate registry status from whether results have been posted on the registry.
Dated snapshot | 14 October 2026 | All registry years | Later registry updates are not reflected
Condition labels contain the case-insensitive text ‘glioblastoma’. This text rule is reproducible, but does not identify every clinically relevant study. Interventional, observational and expanded-access records are included.
Completion and results
are different states.
Both tracks run from 0% to 100% of their stated denominator. A record without posted registry results may have publications elsewhere, may not yet be due to report, or may fall outside a reporting requirement. This view does not assess compliance, study quality or whether an intervention works.
Look at the shape
of the registered work.
Bars compare record counts from zero. Combined phases are kept together as one group; they are not counted twice. “Not applicable” and “not recorded” remain distinct.
Methods, query, source and interpretation
NEUVIOR analysis of public ClinicalTrials.gov API v2 metadata. Saved query: query.cond=glioblastoma. Three pages at 1,000 records per page returned 2,273 unique NCT identifiers, matching the API total, with no next-page token. The projected fields include condition labels, record type, status, phase, results-posted flag and registry dates. No participant records, contacts, interventions or outcomes were requested.
The explicit-label subset contains a submitted condition label with the case-insensitive text “glioblastoma”. The broader search can use registry term expansion and include mixed cancer or CNS studies. Neither cohort is a systematic review or an estimate of all global glioblastoma research.
Status counts describe registration metadata. The API hasResults flag describes results posted on this registry, not positive results, regulatory approval or publication elsewhere. Each combined phase is treated as an exclusive category. Missing phases are preserved. Record-type and condition controls define the denominator; selecting a bar only changes the linked sample.
Source: US National Library of Medicine, ClinicalTrials.gov (2026), condition-search snapshot saved 14 October 2026. The source API reported its data timestamp as 13 October 2026; each study has its own registry update date. This dated snapshot may not reflect the most current or accurate registry data. NLM does not endorse NEUVIOR. API documentation | NLM attribution and reuse terms.
Download the sourced registration metadataInspect the current condition search
Resource Economics | The factor and its boundary
One factor.
One stated boundary.
A conversion is useful when its activity, unit and scope match the question. Inspect a real reference row, then optionally enter a matching measured quantity.
1.2 | July revised flat file | Three selected rows from the 2026 DESNZ flat file. Changing the activity clears the quantity so a different unit is not reused silently.
DESNZ | 2026 published reference
0.13096kg CO2e per kWh
Electricity generated | Electricity: UK
Source classification: Scope 2
Factors by Category | Workbook row 3066
Generation is one part of the electricity boundary.
This row converts a matching electricity quantity in kWh using the published UK electricity-generated factor.
Separate transmission, distribution and well-to-tank factors are excluded. This is not a full-grid lifecycle result or a complete purchased-electricity footprint.
Optional | A single-activity scenario
Use kWh for the defined electricity activity. A tariff, bill total or power rating in kW is not the same quantity.
Start with the activity record
The quantity is yours to establish.
No quantity entered. Choose a matching activity and unit before calculating.
What should a professional check next?
Confirm the activity period, geography and reporting boundary before selecting any additional factors. Do not describe this single-row estimate as the whole impact of an electrical process.
Keep the measurement period, source record and factor edition together. A change in the selected factor is not evidence of an operational improvement; a reduction claim would need a comparable baseline and the relevant wider boundary.
Inspect the method and source edition
Calculation: entered activity quantity × the selected published factor = kg CO2e for that activity boundary. Factors are preserved as retained in the source rows. Displayed results use up to eight significant digits; that display precision does not establish measurement accuracy.
The input starts blank. Zero is accepted as an explicit quantity; a missing value is not treated as zero. Negative, non-finite, non-numeric and unrepresentable quantities or results are rejected. No scenario input is sent or saved, and the component never adds the electricity and water rows into an organisation total.
Source: Department for Energy Security and Net Zero (2026), greenhouse-gas conversion factors, version 1.2 | July revised flat file. Worksheet: Factors by Category. Selected factor ID: 7_400_4000_5_1. Inspect the retained official workbook.
Contains public sector information licensed under the Open Government Licence v3.0. DESNZ (2026) | Publication and methodology.
Source catalogue
Know what sits
behind the view.
Different sources answer different questions.
A weekly product dictionary, a monthly prescribing table and an annual national analysis have different clocks and different meanings. We record the distinction before combining them.
Catalogue checked 14 October 2026 | Source cadence is the publisher’s schedule. It is not a claim of an active NEUVIOR refresh service.
NHS Business Services Authority
Prescription Cost Analysis
Analysis availableHow does activity differ from ingredient-cost concentration?
England community dispensing; financial-year totals and product classifications
- Publisher cadence
- Annual
- Observed edition or reporting period
- 2025/26
- Local retrieval
- Verified 13 October 2026 | 16,227,353 bytes
- Reuse basis
- Open Government Licence v3.0
Read scope, status and citation
21 chapter rows and 1,944 medicinal chemical-substance rows analysed. All 15 medicinal chapters reconcile to the original workbook.
NIC is not final NHS expenditure or pharmacy margin; items are not patients.
The original transfer completion time was not separately retained. The recorded local verification date and file hash establish this snapshot’s custody.
NHS Business Services Authority (2026) Prescription Cost Analysis. Available at: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england/prescription-cost-analysis-england-202526 (Accessed: 13 October 2026).
Retrieved snapshot SHA-256: 56d842e23c458a4cedaf1dec9de0200b5f1b26a3bccb795dc0f0069d7ccde6fe
NHS Business Services Authority
English Prescribing Dataset with SNOMED Code
Metadata retrievedWhich product and organisational patterns merit a closer investigation?
Prescriptions issued in England, with the publisher’s stated community-dispensing coverage
- Publisher cadence
- Monthly
- Observed edition or reporting period
- July 2026
- Local retrieval
- Retrieved 13 October 2026 | 705,159 bytes
- Reuse basis
- Open Government Licence v3.0
Read scope, status and citation
Current replacement for the retired English Prescribing Dataset. Metadata and resource catalogue retrieved; monthly prescribing files have not been ingested.
Latest observed monthly resource is 7,788,728,408 bytes; bulk acquisition needs a storage and validation plan.
A limit-zero metadata request verified the July 2026 datastore schema, including SNOMED_CODE as STRING. No prescribing rows were fetched.
NHSBSA corrected SNOMED_CODE to string, including a reintroduced April 2026 issue. Preserve identifier strings and re-run affected outputs.
EPD and PCA differ in prescribing versus dispensing coverage; national totals cannot be joined without checking definitions.
NHS Business Services Authority (n.d.) English Prescribing Dataset with SNOMED Code. Available at: https://opendata.nhsbsa.net/dataset/english-prescribing-dataset-epd-with-snomed-code (Accessed: 13 October 2026).
Retrieved snapshot SHA-256: 92a7e98721d6913a8bd6cb8eb8ded1d7f2c2940ec4f491942a10cd44063c8756
Medicines and Healthcare products Regulatory Agency
Medicines and device safety communications
Snapshot retrievedWhich official communication should a responsible team read next?
Official recalls, device communications, field safety notices and patient safety alerts
- Publisher cadence
- Event-driven; monthly roundup also published
- Observed edition or reporting period
- Feed updated 13 October 2026
- Local retrieval
- Retrieved 13 October 2026 | 34,672 bytes
- Reuse basis
- Open Government Licence v3.0
Read scope, status and citation
Bounded feed snapshot: 50 entries, not the complete historical inventory. Source updated timestamps are not necessarily first issue dates.
Snapshot indexing is not a recall-compliance service, product-level match or clinical recommendation. Always read the current full official communication.
Medicines and Healthcare products Regulatory Agency (n.d.) Medicines and device safety communications. Available at: https://www.gov.uk/drug-device-alerts (Accessed: 13 October 2026).
Retrieved snapshot SHA-256: 1ffa6e8432320fa23b9ac94d99ba17fe75bb5da6f69da62c8d008d18959c4615
NHS Business Services Authority and NHS England
Dictionary of medicines and devices
Access reviewCan the same product identity be followed consistently across sources?
UK medicinal products and devices; structured product and pack identities
- Publisher cadence
- Weekly
- Observed edition or reporting period
- Guidance checked; release not acquired
- Local retrieval
- Retrieved 13 October 2026 | 69,673 bytes
- Reuse basis
- Open Government Licence v3.0
Read scope, status and citation
Guidance retrieved. Full weekly XML release not downloaded. TRUD registration and applicable download terms must be completed through the normal route.
dm+d content has OGL coverage in the NHS terminology licence table; that does not make all SNOMED CT content openly redistributable.
NHS Business Services Authority and NHS England (n.d.) Dictionary of medicines and devices. Available at: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/nhs-dictionary-medicines-and-devices-dmd (Accessed: 13 October 2026).
Retrieved snapshot SHA-256: 8377c3d340458095782d4538dc244cd8a37acc39f57175650fc5135dd325a93d
NHS England and SNOMED International
SNOMED CT UK edition and Drug Extension
Licence requiredWhat does a concept mean in the correct edition and release?
Clinical terminology, relationships and UK medicinal terminology
- Publisher cadence
- Edition-specific; UK Drug Extension every four weeks
- Observed edition or reporting period
- No terminology release acquired
- Local retrieval
- No data file or API snapshot retrieved
Read scope, status and citation
No full SNOMED terminology download, licence acceptance or registration performed.
Public SNOMED identifiers within an OGL prescribing table do not establish permission to redistribute the complete terminology or deploy it internationally.
NHS England and SNOMED International (n.d.) SNOMED CT UK edition and Drug Extension. Available at: https://digital.nhs.uk/services/terminology-and-classifications/snomed-ct (Accessed: 13 October 2026).
NHS Business Services Authority
BNF and SNOMED mapping
Source identifiedDo codes join to the correct product level and reporting month?
VMP, AMP, VMPP and AMPP records with BNF mappings
- Publisher cadence
- Monthly
- Observed edition or reporting period
- July 2026 data, published September 2026
- Local retrieval
- No data file or API snapshot retrieved
Read scope, status and citation
Publisher plans a phased migration to the Open Data Portal from October 2026; the connector must tolerate a changed publication location.
Mapping file not downloaded; no joins or match-rate claims made.
NHS Business Services Authority (n.d.) BNF and SNOMED mapping. Available at: https://www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/bnf-snomed-mapping (Accessed: 13 October 2026).
NHS Business Services Authority
Discharge Medicines Service claims
Source identifiedWhere do claim stages warrant an operational evidence question?
Claim-submission month, complete and incomplete pharmacy claims; ICB summaries
- Publisher cadence
- Monthly
- Observed edition or reporting period
- July 2026 listed
- Local retrieval
- No data file or API snapshot retrieved
- Reuse basis
- File-specific reuse terms to verify
Read scope, status and citation
No claim files ingested. Claim submission month is not necessarily referral month or completion month.
Counts are not referral-denominator conversion rates or clinical outcomes.
NHS Business Services Authority (n.d.) Discharge Medicines Service claims. Available at: https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/nhs-discharge-medicines-service (Accessed: 13 October 2026).
NHS Business Services Authority
New Medicine Service claims
Source identifiedHow does recorded service activity compare with an organisation’s defined eligible opportunity?
Claimed service activity and ICB or contractor reporting
- Publisher cadence
- Monthly
- Observed edition or reporting period
- July 2026 listed
- Local retrieval
- No data file or API snapshot retrieved
- Reuse basis
- File-specific reuse terms to verify
Read scope, status and citation
No claim files ingested. The publisher describes an April 2025 change to intervention and follow-up consultation reporting.
A claim is not evidence of adherence improvement, a complete clinical pathway or unfilled customer demand.
NHS Business Services Authority (n.d.) New Medicine Service claims. Available at: https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/complete-new-medicine-service-data (Accessed: 13 October 2026).
NHS Business Services Authority
Drug Tariff
Source identifiedWhich reimbursement definition applies in the month under review?
England and Wales reimbursement rules, listed products and prices
- Publisher cadence
- Monthly, with published updates
- Observed edition or reporting period
- October 2026 Part IX listed
- Local retrieval
- No data file or API snapshot retrieved
- Reuse basis
- Publication-specific reuse terms to verify
Read scope, status and citation
Tariff files not ingested or converted into a pricing service.
Tariff reimbursement is not a pharmacy’s acquisition price, realised margin or a universal medicines price.
NHS Business Services Authority (n.d.) Drug Tariff. Available at: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff (Accessed: 13 October 2026).
Department for Energy Security and Net Zero
Greenhouse-gas conversion factors 2026
Dataset retrievedWhich dated factor and accounting boundary fit a measured resource activity?
UK activity-based greenhouse-gas reporting factors for 2026
- Publisher cadence
- Annual, with revision notices
- Observed edition or reporting period
- 2026 factors; revised flat file 31 July 2026
- Local retrieval
- Retrieved 14 October 2026 | 515,426 bytes
- Reuse basis
- Open Government Licence v3.0
Read scope, status and citation
Revised 515,426-byte flat workbook retrieved. Selected factor reference rows extracted; no company emissions inventory or savings result computed.
July correction distinguishes unavailable values from erroneous zeros. Missing factors must stay missing.
PMI, energy demand and greenhouse-gas emissions measure different things. A material ratio is not a carbon calculation.
Department for Energy Security and Net Zero (2026) Greenhouse-gas conversion factors 2026. Available at: https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2026 (Accessed: 14 October 2026).
Retrieved snapshot SHA-256: a9a455ab396dae226d510c7be6233748416d490c41a5d20f3dc7a0c45feecd5e
American Chemical Society | Green Chemistry Institute
Process Mass Intensity method
Method referenceWhich material inputs dominate a process, including water?
Material input mass per mass of isolated product within a consistent process boundary
- Publisher cadence
- Method reference; inspect dated guidance
- Observed edition or reporting period
- Method article published 16 October 2014
- Local retrieval
- No data file or API snapshot retrieved
Read scope, status and citation
NEUVIOR implements the published arithmetic in its educational resource explorer. Worked-example inputs are explicitly invented.
No ACS industrial benchmark dataset, certification, source software redistribution or NEUVIOR process-performance result is claimed.
American Chemical Society | Green Chemistry Institute (2014) Process Mass Intensity method. Available at: https://www.acs.org/green-chemistry-sustainability/green-chemistry-nexus/articles/process-mass-intensity-calculation-tool.html (Accessed: 14 October 2026).
European Medicines Agency
Chemistry of active substances guideline
Document retrievedWhat process, recovered-material and impurity controls belong in a resource proposal?
EMA/CHMP/QWP/49484/2026; adopted 16 February, effective 1 September 2026
- Publisher cadence
- On guideline revision
- Observed edition or reporting period
- 2026 guideline; effective 1 September 2026
- Local retrieval
- Retrieved 14 October 2026 | 362,672 bytes
Read scope, status and citation
Current guideline PDF retrieved and version identified. This is regulatory context, not an industrial measurement dataset.
A recovered input still needs product-specific process and quality evaluation. Source citation does not establish programme regulatory approval.
European Medicines Agency (2026) Chemistry of active substances guideline. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-chemistry-active-substances_en.pdf (Accessed: 14 October 2026).
Retrieved snapshot SHA-256: a980209d02ee120c09a0c32f7362f1101739067cc0a1c954d498625a5eab85b4
Open Targets
Open Targets Platform
Source identifiedWhich published associations support a research hypothesis, and through what evidence?
Integrated target–disease evidence and annotations
- Publisher cadence
- Quarterly platform releases
- Observed edition or reporting period
- Platform 26.9 shown; no data acquired
- Local retrieval
- No data file or API snapshot retrieved
- Reuse basis
- CC0 1.0; inspect source provenance and terms
Read scope, status and citation
No target rankings or GLIO association analysis downloaded in this foundation.
Association scores integrate heterogeneous evidence and are not treatment effectiveness, causal proof or proprietary NEUVIOR findings.
Open Targets (n.d.) Open Targets Platform. Available at: https://platform.opentargets.org/ (Accessed: 13 October 2026).
US National Library of Medicine
ClinicalTrials.gov public study records
Analysis availableWhich GLIO study designs and eligibility patterns merit scientific review?
Bounded glioblastoma condition-search metadata, explicit-label subset and record-type views
- Publisher cadence
- Source records updated by responsible parties; API refresh is source-controlled
- Observed edition or reporting period
- 14 October 2026 snapshot; all registry years
- Local retrieval
- Retrieved 14 October 2026 | 2,066,351 bytes
Read scope, status and citation
A complete bounded condition search returned 2,273 unique public records across three pages; 1,773 contain an explicit glioblastoma condition label. The API reported its source data timestamp as 13 October 2026, separately from our 14 October retrieval.
Search matches can include broader cancer or CNS studies. Completion and registry results posting are separate facts.
No participants, contacts, interventions, outcomes or private NEUVIOR hypotheses were requested or analysed.
Dated snapshot may not reflect current or accurate registry data. NLM is acknowledged as the source and does not endorse NEUVIOR.
US National Library of Medicine (n.d.) ClinicalTrials.gov public study records. Available at: https://clinicaltrials.gov/data-api/about-api (Accessed: 14 October 2026).
Retrieved snapshot SHA-256: 2d5286bdffd1bff59b0984b71abab5c871734c19aef159d7344ebbd74d79f9d7
Three kinds of work
An observation
is the beginning.
Keep the next step honest and useful.
A pattern in public data can sharpen a conversation. It can help define what to study, which information is missing and what change would matter. It does not establish what a product delivers in practice.
Public analysis
Reproducible calculations from a named public source, with dates, scope and methods.
Research hypothesis
An interpretation or proposed question requiring independent testing.
Evidence study
A separately designed investigation; planned, running and completed status must be evidenced.
From a national pattern
to your organisation’s question.
For a pharmacy team, that might be a medicines mix or a service pathway. For an NHS medicines team, it might be a product grouping, an implementation question or the evidence needed before a pilot. For researchers, it might be the strength and limits of a published association.
The public layer is designed to make the first conversation more specific. Any local evaluation needs its own permission, scope, comparison and measures. It belongs to a separate piece of work.
Within PHARMORIS, that connection between evidence, responsibility and action is the direction we are developing. Discuss a data or evaluation question.
